Tech Company Financing Transactions
Rubius Therapeutics Funding Round
Rubius Therapeutics closed a $120 million investment round on 6/22/2017. Investors included Flagship Pioneering and private investors.
Transaction Overview
Company Name
Announced On
6/22/2017
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Flagship Pioneering (Noubar Afeyan)
Proceeds Purpose
Proceeds will be used to accelerate the advancement of Rubius' breakthrough Red-Cell Therapeutics (RCT) product portfolio, to further build out the team and to prepare to enter human clinical trials in 2018.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
325 Vassar St. 1A
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Rubius is developing a new class of drugs, Red-Cell Therapeutics, for the treatment of a wide array of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pablo Cagnoni
Chief Financial Officer
Andrew Oh
Chief Medical Officer
Chris Carpenter
President
Torben Nissen
VP - Bus. Development
Nathan Dowden
VP - Finance
Joanne Protano
VP - Manufacturing
Spencer Fisk
VP - Manufacturing
Robert Konopacz
VP - R & D
Thomas Wickham
Browse more venture capital transactions:
Prev: 6/22/2017: Lingokids venture capital transaction
Next: 6/22/2017: Celtra venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs